Transparency Market Research Report Added "Platelet Rich Plasma Market" to its database.
Albany, NY -- (SBWIRE) -- 06/21/2016 -- A study on the Europe platelets rich plasma (PRP) market has been recently published by Transparency Market Research (TMR). According to this report, the PRP market in Europe was valued at US$42.1 mn in 2013. Analysts project this market to rise at a CAGR of 8.30% during the period from 2014 to 2022 and reach US$87.2 mn by the end of the forecast period.The research report is titled "Platelet Rich Plasma Market - Europe Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 - 2022."
Platelet-rich plasma (PRP) is the kind of blood plasma that contains a high number of platelets. As PRP is a concentrated source of autologous platelets, it contains a higher number of growth factors compared to normal blood concentration and other cytokines that activate healing of soft tissues and bones. It is widely utilized in the treatment of orthopedic disorders, neurological diseases, and various other injuries that require surgeries.
The rising prevalence of obesity and cardiovascular, neurological, and orthopedic disorders, the increasing cases of sports injuries, and the introduction of innovative and advanced devices for PRP preparation in Europe are bolstering the PRP market in this region. Additionally, the growing awareness among the European citizens regarding the PRP therapy and the benefits it offers is expected to support this market during the forecast period, notes the study.
In this report, the Europe PRP market has been studied on the basis of the region, PRP type, origin, and application. Regionally, the Europe market for PRP has been segmented into the U.K., Spain, France, Italy, Germany, and the Rest of Europe.
In 2013, the U.K. emerged as the leading domestic PRP market in Europe. The increase in orthopedic and reconstructive procedures, together with the rising number of bariatric surgeries, has boosted the U.K. PRP market significantly in the recent times. In addition to this, the increasing preference for PRP therapy in cases of sports injuries is likely to aid this market during the forecast period, states the research report.
Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4761
Based on the type of PRP, the market has been classified into pure-platelet rich plasma (P-PRP), leukocyte-platelet rich fibrin (L-PRF), and leukocyte-platelet rich plasma (L-PRP). By origin, it has been segmented into allogenic, autologous, and homologous PRP. On the basis of application, the report has categorized the market into neurosurgery, cosmetic surgery, orthopedic surgery, general surgery, and various other surgeries such as cardiothoracic, oral, maxillofacial, urological, and periodontal surgeries.
The study also presents an assessment of the competitive landscape prevalent in the Europe PRP market. Based on in-depth research it has been stated that the market is highly fragmented due to the presence of a number of small as well as large international participants. Arthrex Inc. led the overall market in 2013. The company's strong emphasis on marketing and distribution strategies in various European nations such as Italy, the U.K., the Netherlands, Spain, France, Germany, and Denmark has helped it significantly to achieve this position.
Other key market participants mentioned in this study are Stryker Corp., Regen Lab S.A., Medira Ltd., Harvest Technologies Corp., Glofinn Oy, DePuy Synthes Inc., Biomet Inc., and AdiStem Ltd.
The Europe market for PRP is segmented into:
Pure-Platelet Rich Plasma (P-PRP)
Leukocyte-Platelet Rich Plasma (L-PRP)
Leukocyte-Platelet Rich Fibrin (L-PRF)
Other Surgeries (Oral and Maxillofacial, Cardiothoracic, Periodontal and Urological)
Rest of Europe
Mr. Sudip S
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453